Asthma and lower airway diseaseQuantitative computed tomography–derived clusters: Redefining airway remodeling in asthmatic patients
Key words
Abbreviations used
Cited by (0)
Supported in part by GlaxoSmithKline, Wellcome Trust Senior Fellowship, and the Airway Disease Predicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (funded through FP7 EU grant). This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.
Disclosure of potential conflict of interest: I. D. Pavord has received research support from, consulting fees from, and travel fees from GlaxoSmithKline (GSK); is a board member for and has consultancy arrangements with Almirall, AstraZeneca, Boehringer Ingelheim, 220 GSK, MSD, Schering-Plough, Novartis, Dey, and Napp; and has received one or more payments for lecturing from or is on the speakers' bureau for AstraZeneca, Boehringer Ingelheim, GSK, Boston Scientific, and Aerocrine. R. P. Marshall is employed by and owns stock/stock options in GSK. D. Subramanian has received one or more payments for lecturing from or is on the speakers' bureau for GSK and has received one or more payments for travel/accommodations/meeting expenses from Talecris Biopharmaceuticals and GSK. D. Parr has consultancy arrangements with and has received one or more payments for lecturing from or is on the speakers' bureau for GRIFOLS/TALECRIS and has received one or more payments for travel/accommodations/meeting expenses from Boehringer Ingelheim. S. Siddiqui is a board member for Teva; has received small-airway research grants from Chiesi; has received one or more payments for lecturing from the European Respiratory Society and in EAACI symposia/PG courses and for lectures organized by Chiesi and GSK and in dry powder inhaler industry symposia; and has received one or more payments for the development of educational presentations for GSK (airway physiology course educational grants). C. E. Brightling has been supported by one or more grants from the Wellcome Trust and GSK; is a Board member for MedImmune, Novartis, Chiesi, and Amgen; and has consultancy arrangements with MedImmune, Roche, and Chiesi. The rest of the authors declare that they have no relevant conflicts of interest.